Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies operates at the intersection of medical devices, digital health, movement-disorder monitoring, and physiological research instrumentation. Its differentiation is breadth within a focused clinical domain: Kinesia products measure and monitor Parkinson's disease and other movement-disorder symptoms, while BioRadio addresses wireless physiological data acquisition for research and education. The company also combines wearable sensors, wireless connectivity, mobile applications, and web-based workflows rather than focusing on a single standalone device. This gives it potential relevance across hospitals, physicians, universities, researchers, and telemedicine programs. Its patent portfolio, including 61 granted patents, indicates a substantial intellectual-property base in movement-disorder assessment and remote therapy tuning.

The company's trajectory shows a long product-development cycle followed by renewed non-dilutive funding. Founded in 2010, Great Lakes NeuroTechnologies has developed products across clinical assessment, continuous remote monitoring, smartphone-based symptom tracking, and physiological research. Its disclosed funding history includes a $1.9 million grant in 2015 and a substantially larger $2.1 million grant on Aug 28, 2025, a ten-year gap that suggests milestone-based financing rather than a conventional venture sequence. The 2025 award is an important inflection point because it specifically supports deep-brain-stimulation programming, extending the company's movement-disorder capabilities beyond symptom measurement into therapy optimization. Patent activity from 2021 through 2023 also indicates sustained investment in remote tuning, symptom quantification, and wearable stimulation technologies. The company reports an employee range of 11 to 50, while only three current positions are specifically identified, so workforce expansion cannot be confirmed. Hiring news is unavailable and there is no reported recent layoff activity. Overall, the evidence supports steady technology and intellectual-property development, with grant-backed acceleration in neurological therapy applications rather than documented rapid commercial scaling.